Belyea to step down as Metabolic CEO

By Renate Krelle
Thursday, 13 January, 2005

Obesity drug-developer Metabolic (ASX:MBP) announced today that the company is searching for a new CEO and that when an appointment is made, founding CEO Chris Belyea will move into a "scientific and technical" role within the company.

The company said Belyea had expressed his desire to relinquish the CEO role in August 2004. Board chairman Arthur Emmett has since been undertaking the search for a new CEO.

Link between oestrogen and heart health found in women

Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...

Frequent nightmares accelerate aging, increase risk of death

Nghtmares independently predict faster biological aging and earlier mortality — even after...

Cardiac organoids bring hope for treating heart disease

Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...

Content from other channels on our network

CSIRO launches National Energy Analysis Centre

Wastewater contaminants can boost hydrogen production: research

Transgrid finalises system strength plan

CSIRO spin-off targets future health ingredients with precision fermentation

Queensland launches manufacturing advisory council

Graph-Pak solutions on show at CeMAT

Jack Link's APAC buys beef stick brand KOOEE! Snack Foods

Automation system designed to guide bottles without breakage

Post-harvest tech to extend storage life of mangoes

How Australian manufacturers can combat staffing challenges in FY2026 and beyond

AI use in the future of water treatment systems: study

Australia can heavily cut emissions by 2035: report

Qld waterways to be revitalised ahead of Brisbane 2032

Planning approval for B2B green hydrogen facility

Digital retrofits driving a new era of sustainable buildings